NeuroPace (NASDAQ:NPCE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of NeuroPace (NASDAQ:NPCE) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

NPCE has been the topic of a number of other research reports. Cantor Fitzgerald upgraded NeuroPace to a “strong-buy” rating in a research note on Wednesday, March 4th. UBS Group reaffirmed a “buy” rating on shares of NeuroPace in a research report on Wednesday, January 14th. JPMorgan Chase & Co. lifted their price target on NeuroPace from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. HC Wainwright boosted their price objective on NeuroPace from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.67.

NeuroPace Stock Up 0.1%

NPCE opened at $14.05 on Friday. The company has a debt-to-equity ratio of 3.09, a current ratio of 5.28 and a quick ratio of 4.33. The company’s 50-day moving average is $15.51 and its 200 day moving average is $13.41. NeuroPace has a fifty-two week low of $7.56 and a fifty-two week high of $18.98. The firm has a market capitalization of $473.06 million, a P/E ratio of -21.29 and a beta of 1.86.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The business had revenue of $26.59 million for the quarter, compared to analysts’ expectations of $24.79 million. NeuroPace had a negative net margin of 21.47% and a negative return on equity of 105.67%. Research analysts expect that NeuroPace will post -1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its stake in NeuroPace by 83.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock valued at $27,000 after purchasing an additional 1,118 shares during the last quarter. Legal & General Group Plc increased its position in NeuroPace by 86.0% in the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after buying an additional 1,239 shares during the last quarter. GSA Capital Partners LLP increased its position in NeuroPace by 2.5% in the third quarter. GSA Capital Partners LLP now owns 54,536 shares of the company’s stock worth $562,000 after buying an additional 1,323 shares during the last quarter. Quarry LP raised its stake in shares of NeuroPace by 94.9% in the third quarter. Quarry LP now owns 3,845 shares of the company’s stock valued at $40,000 after buying an additional 1,872 shares during the period. Finally, Man Group plc raised its stake in shares of NeuroPace by 9.7% in the fourth quarter. Man Group plc now owns 21,626 shares of the company’s stock valued at $334,000 after buying an additional 1,920 shares during the period. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.